PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer - PubMed (original) (raw)
Clinical Trial
. 2013 Dec 10;31(35):4400-6.
doi: 10.1200/JCO.2013.49.7685. Epub 2013 Oct 14.
Robert L Coleman, Robert A Burger, Edward A Sausville, Elzbieta Kutarska, Sharad A Ghamande, Nashat Y Gabrail, Stephen E Depasquale, Elzbieta Nowara, Lucy Gilbert, Robert H Gersh, Michael G Teneriello, Wael A Harb, Panagiotis A Konstantinopoulos, Richard T Penson, James T Symanowski, Chandra D Lovejoy, Christopher P Leamon, David E Morgenstern, Richard A Messmann
Affiliations
- PMID: 24127448
- DOI: 10.1200/JCO.2013.49.7685
Clinical Trial
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer
R Wendel Naumann et al. J Clin Oncol. 2013.
Abstract
Purpose: Vintafolide (EC145) is a folic acid-desacetylvinblastine conjugate that binds to the folate receptor (FR), which is expressed on the majority of epithelial ovarian cancers. This randomized phase II trial evaluated vintafolide combined with pegylated liposomal doxorubicin (PLD) compared with PLD alone. The utility of an FR-targeted imaging agent, (99m)Tc-etarfolatide (EC20), in selecting patients likely to benefit from vintafolide was also examined.
Patients and methods: Women with recurrent platinum-resistant ovarian cancer who had undergone ≤ two prior cytotoxic regimens were randomly assigned at a 2:1 ratio to PLD (50 mg/m(2) intravenously [IV] once every 28 days) with or without vintafolide (2.5 mg IV three times per week during weeks 1 and 3). Etarfolatide scanning was optional. The primary objective was to compare progression-free survival (PFS) between the groups.
Results: The intent-to-treat population comprised 149 patients. Median PFS was 5.0 and 2.7 months for the vintafolide plus PLD and PLD-alone arms, respectively (hazard ratio [HR], 0.63; 95% CI, 0.41 to 0.96; P = .031). The greatest benefit was observed in patients with 100% of lesions positive for FR, with median PFS of 5.5 compared with 1.5 months for PLD alone (HR, 0.38; 95% CI, 0.17 to 0.85; P = .013). The group of patients with FR-positive disease (10% to 90%) experienced some PFS improvement (HR, 0.873), whereas patients with disease that did not express FR experienced no PFS benefit (HR, 1.806).
Conclusion: Vintafolide plus PLD is the first combination to demonstrate an improvement over standard therapy in a randomized trial of patients with platinum-resistant ovarian cancer. Etarfolatide can identify patients likely to benefit from vintafolide.
Trial registration: ClinicalTrials.gov NCT00722592.
Similar articles
- Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J. Lawrie TA, et al. Cochrane Database Syst Rev. 2013 Jul 9;2013(7):CD006910. doi: 10.1002/14651858.CD006910.pub2. Cochrane Database Syst Rev. 2013. PMID: 23835762 Free PMC article. Updated. Review. - Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pujade-Lauraine E, et al. J Clin Oncol. 2010 Jul 10;28(20):3323-9. doi: 10.1200/JCO.2009.25.7519. Epub 2010 May 24. J Clin Oncol. 2010. PMID: 20498395 Clinical Trial. - Vintafolide: a novel targeted agent for epithelial ovarian cancer.
Graybill WS, Coleman RL. Graybill WS, et al. Future Oncol. 2014 Mar;10(4):541-8. doi: 10.2217/fon.14.8. Future Oncol. 2014. PMID: 24754586 - Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
Ambrosio AJ, Suzin D, Palmer EL, Penson RT. Ambrosio AJ, et al. Expert Rev Clin Pharmacol. 2014 Jul;7(4):443-50. doi: 10.1586/17512433.2014.909723. Epub 2014 Apr 18. Expert Rev Clin Pharmacol. 2014. PMID: 24742319 Review.
Cited by
- Renal Reabsorption of Folates: Pharmacological and Toxicological Snapshots.
Samodelov SL, Gai Z, Kullak-Ublick GA, Visentin M. Samodelov SL, et al. Nutrients. 2019 Oct 2;11(10):2353. doi: 10.3390/nu11102353. Nutrients. 2019. PMID: 31581752 Free PMC article. Review. - Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases.
Frigerio B, Bizzoni C, Jansen G, Leamon CP, Peters GJ, Low PS, Matherly LH, Figini M. Frigerio B, et al. J Exp Clin Cancer Res. 2019 Mar 12;38(1):125. doi: 10.1186/s13046-019-1123-1. J Exp Clin Cancer Res. 2019. PMID: 30867007 Free PMC article. - Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer.
Wallace-Povirk A, Hou Z, Nayeen MJ, Gangjee A, Matherly LH. Wallace-Povirk A, et al. Cancers (Basel). 2021 Dec 31;14(1):191. doi: 10.3390/cancers14010191. Cancers (Basel). 2021. PMID: 35008360 Free PMC article. Review. - Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J. Lawrie TA, et al. Cochrane Database Syst Rev. 2013 Jul 9;2013(7):CD006910. doi: 10.1002/14651858.CD006910.pub2. Cochrane Database Syst Rev. 2013. PMID: 23835762 Free PMC article. Updated. Review. - Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.
Notaro S, Reimer D, Fiegl H, Schmid G, Wiedemair A, Rössler J, Marth C, Zeimet AG. Notaro S, et al. BMC Cancer. 2016 Aug 2;16:589. doi: 10.1186/s12885-016-2637-y. BMC Cancer. 2016. PMID: 27485273 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical